MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2015.712 MCO-0-0-712 Articles Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer YUJUNXIU 1 ZHANGSHUGUANG 2 ZHAOBINGBO 1 Department of Gastrointestinal Surgery, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, Shandong 252000, P.R. China Laboratory Department, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, Shandong 252000, P.R. China Correspondence to: Dr Junxiu Yu, Department of Gastrointestinal Surgery, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, 67 West Dongchang Road, Liaocheng, Shandong 252000, P.R. China, E-mail: yujxcn@hotmail.com 03 2016 15 12 2015 4 3 441 449 11082015 27112015 Copyright © 2016, Spandidos Publications 2016

The sensitivity of three biomarkers, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9 and CA72-4, in combination has been identified to be greater than that of any of the biomarkers considered in isolation in cases of gastric cancer (GC). However, the fundamental cause underlying this phenomenon remains to be fully elucidated. In the present study, the differences and correlation of these three biomarkers were investigated in patients with GC in order to determine how the three biomarkers in combination work more effectively compared with any of the biomarkers considered alone. The serum levels of CEA, CA19-9 and CA72-4 of 216 patients with gastric adenocarcinoma were analyzed on admission to hospital. The differences in positive rates and the serum levels of CEA, CA19-9 and CA72-4 were analyzed using the χ2 test and the non-parametric Wilcoxon two-sample test. Phi (f) correlation analysis was used to study the correlation among the expression (positive or not) levels of CEA, CA19-9 and CA72-4. The correlation among the serum levels of biomarkers was analyzed using Spearman's test. The results demonstrated that the combined positive rate of CEA, CA19-9 and CA72-4 was significantly higher compared with the individual CEA, CA19-9 and CA72-4 positive rates (44.91% vs. 22.69, 18.98 and 22.69%, respectively; all P<0.05). The positive rate of CA19-9 and CA72-4 in the extent of the primary tumor/involvement of regional lymph node/distant metastases (TNM)-III/IV stage subgroup was higher compared with that in the TNM-I/II subgroup (χ2=5.902, P=0.015; χ2=8.009, P=0.005), although not the positive rate of CEA (χ2=0.302, P=0.583). A significant correlation was identified between the expression level of CEA and CA72-4 (f correlation coefficient=0.182; P=0.008) and between that of CA19-9 and CA72-4 (f correlation coefficient=0.189; P=0.006), although not between that of CEA and CA19-9 (f correlation coefficient=0.048; P=0.482) in the total number of patients with GC. A significant correlation was also identified between the serum levels of CEA and CA19-9, of CEA and CA72-4 and of CA19-9 and CA72-4 (Spearman's correlation coefficient=0.231, −0.271 and 0.167; P=0.001, P<0.0001 and P=0.014, respectively). The present study indicated that there was only a weak correlation between the positive rate of CEA and CA72-4 and between that of CA19-9 and CA72-4, and no correlation was identified between the positive rate of CEA and CA19-9, even if a correlation was identified between the serum levels of the biomarkers. The present study suggested that the evidence that the sensitivity of the three biomarkers in combination is greater than that of any of the biomarkers taken in isolation is due to less co-presentation of CEA, CA19-9 and CA72-4 in patients with GC.

 gastric cancer tumor marker CEA CA19-9 CA72-4 Introduction

Gastric cancer (GC) is one of most common cancers worldwide, even if the incidence rate is decreasing in certain regions. Almost 951,600 new patients were diagnosed with GC in 2012 (1). The survival rate of patients with GC remains relatively poor, since the majority of cases are already in the late stage at diagnosis, and surgery and chemotherapy result in an unsatisfactory prognosis. Serum tumor markers are useful for diagnosis, for predicting survival rates and for monitoring recurrence following surgery (2,3). Carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9 and CA72-4 are the most frequently used clinical markers. It has been demonstrated that they are useful in the diagnosis, treatment and prognosis of GC (4–8). However, the specificity and sensitivity of serum tumor markers considered in isolation are not satisfactory in GC, particularly in the early stage (9). Therefore, certain researchers have previously used combinations of markers, since they can improve the sensitivity for diagnosis of GC (10–12). Yang et al (13) demonstrated that the sensitivities of CA72-4, CEA, cancer antigen 125 (CA125) and CA19-9 for GC were 33.0, 25.5, 31.1 and 38.7%, respectively. However, the sensitivity of the four markers in combination increased to 66.0%. Similarly, the individual sensitivities of CEA and CA19-9 were 30 and 42%, respectively, although this increased to 58% when CEA and CA19-9 were combined (14). Ychou et al (15) reported a similar result, with a sensitivity of 75% when CA72-4, CEA and CA19-9 were combined. The above results may be explained simply by different markers being positive in different patients. However, to the best of our knowledge, the fundamental cause underlying this phenomenon remains to be fully elucidated. In the present study, the differences and correlation of these three biomarkers in patients with GC were investigated, with the aim to evaluate how the three biomarkers in combination work more effectively than any of the biomarkers considered alone.

 Materials and methods <sec> <title>Patients

A total of 216 patients from Liaocheng People's Hospital (Shandong, China) were enrolled between January 2011 and December 2013. Of the patients, 172 (79.63%) were men and 44 (20.37%) were women. The median age was 62 years (range: 20–85 years). The patients' age, gender, tumor histological type and extent of the primary tumor/involvement of regional lymph node/distant metastases (TNM) stage of the cancer were collected from the medical records. The cohort of patients included those who received radical, palliative surgery or chemotherapy. The tumor histological type was determined on the basis of the Japanese Gastric Cancer Association classification system (2010) (16). The T- and the N-stages were not identified in 23 and 29 of the total patients, respectively, since these patients did not receive a radical gastrectomy. These patients were therefore excluded from the statistical comparison performed for the T- and N-stage groups. Papillary adenocarcinoma and well-/moderately-differentiated tubular adenocarcinoma were classified as differentiated-type carcinoma, whereas poorly differentiated adenocarcinoma, signet ring cell carcinoma and mucinous carcinoma were classified as undifferentiated-type carcinoma. The TNM stage was determined according to the 7th edition of the International Union Against Cancer Classification (2010) (17).

 Biomarkers

The serum levels of CEA, CA19-9 and CA72-4 were detected on admission of the patients to hospital, when the patients had not received any surgery, chemotherapy or radiotherapy. The normal reference values were as follows: CEA, ≤5 ng/ml; CA19-9, ≤39 U/ml; and CA72-4, ≤6.9 U/ml. Patients were considered positive for CEA, CA19-9 or CA72-4 when the serum levels were identified to be greater than the above-mentioned values. Patients were considered positive for the parallel test when the serum level of any of CEA, CA19-9 or CA72-4 was greater than its normal value.

 Statistical analyses

Differences in the positive rates (categorical variables) of CEA, CA72-4 and CA19-9 were analyzed using the χ2 test, and f correlation analysis was used to study the correlation among the expression levels of CEA, CA19-9 and CA72-4. The serum levels of CEA, CA19-9 and CA72-4 were described using median values. The differences in serum levels of the biomarkers were compared using the non-parametric Wilcoxon two-sample test. The correlation between serum levels of biomarkers was analyzed using Spearman's rank correlation coefficient test. All the data were analyzed using SAS version 9.0 software (SAS Institute, Inc., Cary, NC, USA). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Differences and correlation of positive rates of CEA, CA19-9 and CA72-4

The positive rates for CEA, CA19-9 and CA72-4 were 22.69 (49/216), 18.98 (41/216) and 22.69% (49/216). The positive rate of the parallel test of CEA, CA19-9 and CA72-4 was 44.91% (97/216), which was significantly higher compared with the individual CEA, CA19-9 and CA72-4 positive rates (all P<0.05; Fig. 1). In subgroups based on gender, age, histology, T stage, N stage, M stage and TNM stage cancer, the majority of the individual positive rates for CEA, CA19-9 and CA72-4 were significantly lower compared with the parallel test positive rates (P<0.05). However, no significant differences were identified between the parallel test positive rates, the CA19-9 and CA72-4 positive rates in the women patients, or between the parallel test positive rates and the CEA and CA72-4 positive rates in the T1/2 and M1 subgroups (P>0.05).

As shown in Table I, the positive rate of CEA, CA19-9 or CA72-4 did not differ significantly in all 216 patients. In the subgroups, no significant difference was identified in the positive rate of CEA, CA19-9 and CA72-4, with the exception of the T1/2-stage patients (χ2=6.810, P=0.033).

The differences in the positive rates of CEA, CA19-9 and CA72-4 according to gender, age, histology, T stage, N stage, M stage and TNM stage in each subgroup were analyzed using the χ2 test. The positive rate of CEA in the M1 subgroup was higher compared with that in the M0 subgroup. No differences in the positive rate of CEA were identified on the basis of gender, age, histology, T stage, N stage or the TNM stage. The positive rate of CA19-9 in the T3/4, N(+) and TNM-III/IV stage subgroups was higher compared with that in the T1/2, N(−) and TNM-I/II stage subgroups. No differences in the positive rate of CA19-9 were identified according to other clinicopathological classifications. The positive rate of CA72-4 in the T3/4, M1 and TNM-III/IV stage subgroups was higher compared with that in the T1/2, M0 and TNM-I/II stage subgroups (Table I).

The phi (f) correlation analysis demonstrated that no significant correlation existed between the expression levels (positive or not) of CEA and CA19-9 in all 216 patients. However, a significant correlation did exist between the expression levels of CEA and CA72-4, and between that of CA19-9 and CA72-4, in all cases. In all the subgroups, no significant correlation was identified between CEA and CA19-9. However, a significant correlation was identified between the expression level of CEA and CA72-4 in men, in patients aged >60 years, in patients exhibiting an undifferentiated histology and in the M0 subgroup of GC, although not in other subgroups. The majority of the f correlations between the expression levels of CA19-9 and CA72-4 were significant in patients aged ≤60 years, and in those with undifferentiated histology or N(+), M0 or TNM-III/IV stage cancer (Table II).

 Differences and correlation of the serum levels of CEA, CA19-9 and CA72-4

The median serum levels of CEA, CA19-9 and CA72-4 were 2.230 (range, 0.2–152.7) ng/ml, 7.50 (range, 0–1057.9) U/ml and 2.51 (range, 0.503–300.0) U/ml, respectively. The three-dimensional scatter plot is shown in Fig. 2.

The Wilcoxon two-sample test revealed that the serum levels of CEA differed significantly, according to the gender. The serum level of CEA was higher in women compared with men (2.465 vs. 1.175 ng/ml). No significant differences were identified in the serum level of CEA according to age, histology, or the T, N, M or TNM stages of cancer. The serum levels of CA19-9 in the T3/4 and the TNM-III/IV stages were significantly higher compared with those in the T1/2 and the TNM-I/II stages, respectively. The serum level of CA72-4 in the T3/4, M1 and TNM-III/IV stage subgroups was significantly higher than in the T1/2, M0 and TNM-I/II stage subgroups. No significant differences were identified in the serum level of CA19-9 and CA72-4 in the other clinicopathological subgroups. These results are shown in Table III.

Spearman's correlation analysis showed that there were significant correlations between the serum levels of CEA and CA19-9, of CEA and CA72-4, and of CA19-9 and CA72-4 in all 216 patients (Table IV). Regarding the subgroups, there were significant correlations between the serum levels of CEA and CA19-9 in men, women, patients aged >60 years, and those with differentiated tumors, undifferentiated tumors, and T3/4, N(+), M0, TNM-I/II or TNM-III/IV stage cancer, but not in patients aged ≤60 years and those with T1/2, N(−) or M1 stage cancer. In the majority of subgroups, there were significant correlations between the serum levels of CEA and CA72-4, except in the cases of T1/2, N(−) and M1 stage cancer. A significant correlation was identified between the serum levels of CA19-9 and CA72-4 in women patients, those aged ≤60 years, those with undifferentiated tumors and those with N(+), M0 and TNM-III/IV stage cancer, although not in the other subgroups.

 Discussion

CEA was originally described by Gold and Freedman in 1965 (18); it is a glycoprotein that belongs to the immunoglobulin superfamily. CEA is used predominantly for the management of colorectal carcinoma, and its levels may be increased in gastric, lung, pancreatic and breast carcinoma. CA19-9 was first isolated by Koprowski et al (19) in 1979; it is a high-molecular-mass mucin glycoprotein complex that is associated with the Lewis A blood group. CA19-9 is used primarily as a tumor marker for pancreatic cancer, although it has been used as a tumor marker in other gastrointestinal cancers, including colorectal and gastric carcinoma, and gallbladder cancer. It may also be increased in several benign diseases, including pancreatitis and cholelithiasis. CA72-4 was first described by Colcher et al (20) in 1981: It is a glycoprotein with a molecular mass >1000 kDa and is associated with the sialylated Lewis Tn group. It is a tumor marker for numerous cancers, including breast, ovarian, colorectal and pancreatic cancer, and it has good specificity for GC.

No significant differences were identified in the positive rate of CEA, CA19-9 and CA72-4 in all 216 patients, and almost all the subgroups, in the present study. Only ~20% of all the patients with GC exhibited positive rates of CEA, CA19-9 and CA72-4. The results in the present study were similar to those previously obtained: In a systematic review (9) of 187 publications with data for CEA and CA19-9, and 19 publications with data for CEA, CA72-4 and CA19-9, the positive rates were 21.1% for CEA, 27.8% for CA19-9 and 30.0% for CA72-4. In a study of 149 Chinese patients with GC, He et al (10) demonstrated that the positive rates for CEA and CA19-9 were 17.4 and 20.8%, respectively, which were not significantly different. In a subsequent study of Chinese patients with GC, the preoperative serum positive rate of CEA was 24.0%, which was similar to the serum positive rate of CA19-9 (18.9%) (21). Mittal et al (22) demonstrated that the positive rate of CEA was lower compared with that of CA19-9, although no significant differences were identified between the positive rate of CEA and CA72-4, or of CA19-9 and CA72-4. In previous studies (6,23), the positive rate of CEA was determined to be lower compared with that of CA19-9 and CA72-4.

The positive rate of the parallel test for CEA, CA19-9 and CA72-4 was significantly higher compared with the individual positive rates for CEA, CA19-9 and CA72-4 in all 216 patients. In the subgroups, the majority of the parallel test positive rates were also higher compared with the individual CEA, CA19-9, and CA72-4 positive rates.

In the gender, age and histological subgroups, no significant differences were identified in the positive rate of CEA, CA19-9 and CA72-4. The serum levels of CEA, CA19-9 and CA72-4 did not differ significantly on the basis of gender, age or histological classification, with the exception of the serum level of CEA, which differed between the genders. The results of the present study were supported by those of previous studies. No significant differences were identified in the positive rate of CEA, CA19-9 and CA72-4 between men and women, between patients aged <60 and ≥60 years, or among the various histological types (24). Ucar et al (25) demonstrated that no significant differences existed among the positive rates of CEA, CA19-9 and CA72-4, according to gender or the histological type (intestinal or diffuse). Choi et al (8) demonstrated that the positive rate of CA19-9 was not correlated with gender and age, although it was correlated with histological type. Yajima et al (26) identified that the serum levels of CA19-9 did not correlate with gender, age or histological type.

The positive rate of CEA did not increase in association with the progression of GC. The significant difference of the positive rate of CEA was presented only in the M subgroup. No significant differences were identified in the positive rates of CEA according to the T, N or TNM stages of cancer in the present study. These results are supported by previous studies: Cidon et al (23) demonstrated that the positive rate of CEA in early-stage GC did not differ from that in advanced-stage GC. Ucar et al (25) identified that the positive rate did not correlate with the TNM stage of cancer, serosal involvement or the N stage, although it was correlated with liver involvement. However, a number of previous studies indicated that the positive rate of CEA does increase with tumor progression. In a systematic review, Shimada et al (9) revealed that the positive rate of serum CEA was significantly correlated with the TNM stage. Tian et al (27) demonstrated that there were significant differences in the positive rate of serum CEA between the T1/2 and T3/4 stages, and between cases with lymph node metastasis and those with no lymph node metastasis.

The positive rate of CA19-9 increased with the progression of GC. The positive rate of CA19-9 in the T3/4, N(+) and TNM-III/IV subgroups was higher compared with that in the T1/2, N(−) and TNM-I/II subgroups. Shimada et al (9) presented similar results on the basis of a systematic review, which identified that the positive rate of CA19-9 increased with the TNM stage. These results indicated that CA19-9 is an improved marker for GC prognosis (28). Lee et al (11) identified that the positivity of CA19-9 increased significantly with GC progression, similarly to the results in the present study. The positivity of CA19-9 was 4.0% in stage I, 6.8% in stage II, 13.9% in stage III and 24.1% in stage IV GC. A previous study (21) revealed that the positive rate of CA19-9 was not correlated with the T, M or TNM-stage GC cases. Another study demonstrated that there were significant increases in the level of CA19-9 in patients with GC, with direct invasion and extensive peritoneal seeding (29).

The positive rate of CA72-4 increased in accordance with the progression of GC. The positive rate of CA72-4 in the T3/4, M1 and TNM-III/IV subgroups was higher compared with that in the T1/2, M0 and TNM-I/II subgroups. A systematic review by Shimada et al (9) indicated that the positive rate of CA72-4 increased with the TNM stage. The specificity of CA72-4 for GC is higher compared with that of CEA and CA19-9. A meta-analysis of Chinese patients with GC (30) demonstrated that CA72-4 was selected as the preferable single test, with the highest accumulated accuracy among tumor markers, including CA72-4, CA12-5, CA15-3, CA19-9, CA24-2 and CEA. The CA72-4 was identified as a tumor marker for late-stage GC in previous studies. Emoto et al (31) determined that the sensitivity of CA72-4 for the peritoneal metastasis of GC was 45%, which was higher compared with that of CEA and CA19-9. Patients with ovarian metastasis exhibited significantly higher levels of CA72-4 (31).

The serum levels of CA19-9 and CA72-4 increased with tumor progression, although the serum level of CEA did not. CEA was revealed not to be higher in the T3/4, N(+), M1 and TNM-III/IV stages, compared with the T1/2, N(−), M0 and TNM-I/II stages. The serum level of CA19-9 was higher in the T3/4 and TNM-III/IV stages compared with the T1/2 and the TNM-I/II stages. The serum level of CA72-4 was higher in the T3/4, M1 and TNM-III/IV stages compared with the T1/2, M0 and TNM-I/II stages. Subsequently to the aforementioned results, the serum level of CA19-9 and CA72-4 in the TNM-III/IV stage was higher compared with the TNM-I/II stage, although there were conflicting results for the difference in the serum level of CA19-9 and CA72-4 in the T, N and M stages. Han et al (29) identified that the mean values of CEA did not differ significantly among the serosa-unexposed, serosa-exposed, direct invasion and localized peritoneal seeding groups. The mean CEA level was higher in patients with extensive peritoneal seeding. Yajima et al (26) identified that the patients with higher serum levels of CA19-9 presented with advanced T stage, N stage and TNM stage cancer. However, Lee et al (11) revealed that there was a tendency towards increasing CEA levels with advancing stages of cancer, as well as increases in CA19-9 and CA72-4.

In all the patients, the f correlation analysis indicated that there was significant correlation between the expression of CEA and CA72-4, and between CA72-4 and CA19-9. The correlation coefficients between CEA and CA72-4 and between CA72-4 and CA19-9 was <0.2, indicating a weak correlation. No significant correlation was identified between CEA and CA19-9. However, in certain of the subgroups, a significant correlation was identified between the expression of CEA and CA72-4, and between CA19-9 and CA72-4. The results in the present study revealed that CEA, CA19-9 and CA72-4 did not exhibit similar trends in positivity. Statistical analyses revealed that different patients presented with different biomarkers, even if the positive rate was determined to be similar among the three biomarkers.

In all 216 patients, a significant correlation was identified between the serum levels of CEA and CA19-9, of CEA and CA72-4, and of CA19-9 and CA72-4. In the T1/2 stage subgroup, no significant correlations between the serum levels of CEA and CA19-9, of CEA and CA72-4, and of CA19-9 and CA72-4 were identified. In the T3/4 stage subgroup, a significant correlation was identified between the serum level of CEA and CA19-9, and also between that of CEA and CA72-4, and an almost significant correlation existed between CA19-9 and CA72-4 (P=0.056). In the N stage subgroup, a significant correlation was identified between the serum levels of CEA and CA19-9, of CEA and CA72-4, and of CA19-9 and CA72-4 in N(+) stage patients, although not in N(−) stage patients. These results indicated that a significant correlation was identified between the serum levels of CEA, CA19-9 and CA72-4 in the late T and N stages, although not in the early T and N stages. However, the opposite was shown for the M stage. A significant correlation was identified between the serum levels of CEA, CA19-9 and CA72-4 in the M0 stage, although not in the M1 stage. There have been few studies published on the correlation among biomarkers. Han et al (29) obtained different results: Significant correlations between the serum levels of CEA and CA19-9 were identified in their laboratory for most patients, including the serosa-unexposed group (although not the serosa-exposed group), and patients with direct invasion, localized peritoneal seeding and extensive peritoneal seeding.

In conclusion, the present study identified only a weak correlation between the positive rates of CEA and CA72-4, and of CA19-9 and CA72-4, and no correlation was identified between the positive rate of CEA and CA19-9 in all the patients with GC, even if there was a marked correlation between the serum levels of CEA and CA19-9, CA19-9 and CA72-4, and CA19-9 and CA72-4. In addition, the positive rate and serum level of CEA did not increase with tumor progression, although the positive rate and levels of CA19-9 and CA72-4 did increase with tumor progression. These results indicated that different biomarkers presented positive in different cases and during different stages of GC. There was less co-presentation of CEA, CA19-9 and CA72-4 in patients with GC. Therefore, the combined value of the tests, particularly of CA19-9 and CA72-4, is complementary. The sensitivity of the three biomarkers in combination is greater than that of any of the biomarkers taken in isolation.

 Acknowledgements

We would like to thank all members of the staff in the Department of Gastrointestinal Surgery, Department of Pathology and the Medical Record Department for their support in data accumulation.

 References TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin6587108201510.3322/caac.2126225651787 ParkHJAhnJYJungHYLimHLeeJHChoiKSdo KimHChoiKDSongHJLeeGHKimJHClinical characteristics and outcomes for gastric cancer patients aged 18-30 yearsGastric Cancer17649660201410.1007/s10120-013-0331-124414087 NamDHLeeYKParkJCLeeHShinSKLeeSKLeeYCCheongJHHyungWJNohSHKimCBPrognostic value of early postoperative tumor marker response in gastric cancerAnn Surg Oncol2039053911201310.1245/s10434-013-3066-723807661 MohriYTanakaKOhiMSaigusaSYasudaHToiyamaYArakiTInoueYKusunokiMIdentification of prognostic factors and surgical indications for metastatic gastric cancerBMC Cancer14409201410.1186/1471-2407-14-40924906485 KwonOKYuWChungHPrognostic value of postoperative CA19-9 normalization in patients with advanced gastric cancerHepatogastroenterology60240243201322975648 KimDHOhSJOhCAChoiMGNohJHSohnTSBaeJMKimSThe relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomyJ Surg Oncol104585591201110.1002/jso.2191921695697 JoJCRyuMHKooDHRyooBYKimHJKimTWChoiKDLeeGHJungHYYookJHSerum CA 19-9 as a prognostic factor in patients with metastatic gastric cancerAsia Pac J Clin Oncol9324330201310.1111/ajco.1201923176400 ChoiARParkJCKimJHShinSKLeeSKLeeYCChungJBHigh level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancerWorld J Gastroenterol1953025308201310.3748/wjg.v19.i32.530223983433 ShimadaHNoieTOhashiMObaKTakahashiYClinical significance of serum tumor markers for gastric cancer, A systematic review of literature by the task force of the Japanese gastric cancer associationGastric Cancer172633201410.1007/s10120-013-0259-523572188 HeCZZhangKHLiQLiuXHHongYLvNHCombined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancerBMC Gastroenterol1387201310.1186/1471-230X-13-8723672279 LeeJCLeeSYKimCYYangDHClinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancerJ Korean Surg Soc85283289201310.4174/jkss.2013.85.6.28324368986 LiFLiSWeiLLiangXZhangHLiuJThe correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatmentBiomarkers18632637201310.3109/1354750X.2013.84080024066812 YangAPLiuJLeiHYZhangQWZhaoLYangGHCA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancerClin Chim Acta437183186201410.1016/j.cca.2014.07.03425086284 BagariaBSoodSSharmaRLalwaniSComparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)Cancer Biol Med10148157201324379990 YchouMDuffourJKramarAGourgouSGrenierJClinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancerDis Markers16105110200010.1155/2000/59549211381189 Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English editionGastric Cancer14101112201110.1007/s10120-011-0041-521573743 EdgeSBByrdDRComptonCCFritzAGGreeneFLTrottiAAJCC Cancer Staging HandbookNew YorkSpringer2010 GoldPFreedmanSODemonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniquesJ Exp Med121439462196510.1084/jem.121.3.43914270243 KoprowskiHSteplewskiZMitchellKHerlynMHerlynDFuhrerPColorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell Genet5957971197910.1007/BF0154265494699 ColcherDHandPHNutiMSchlomJA spectrum of monoclonal antibodies reactive with human mammary tumor cellsProc Natl Acad Sci USA7831993203198110.1073/pnas.78.5.31996789331 HuangZBZhouXXuJDuYPZhuWWangJShuYQLiuPPrognostic value of preoperative serum tumor markers in gastric cancerWorld J Clin Oncol5170176201410.5306/wjco.v5.i2.17024829865 MittalAGuptaSPJhaDKSathianBPoudelBImpact of various tumor markers in prognosis of gastric cancer. HistopathologyAsian Pac J Cancer Prev1419651967201310.7314/APJCP.2013.14.3.196523679300 CidónEUBustamanteRGastric cancer: Tumor markers as predictive factors for preoperative stagingJ Gastrointest Cancer42127130201110.1007/s12029-010-9161-020499209 LiuXCaiHWangYPrognostic significance of tumour markers in Chinese patients with gastric cancerANZ J Surg84448453201410.1111/j.1445-2197.2012.06287.x23013163 UcarESemerciEUstunHYetimTHuzmeliCGulluMPrognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancerAdv Ther2510751084200810.1007/s12325-008-0100-418821070 YajimaHOmuraNMataiKMitsumoriNYoshidaKYanagaKClinicopathological features of CA19-9-producing gastric cancerHepatogastroenterology61221225201424895825 TianSBYuJCKangWMMaZQYeXCaoZJYanCCombined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancerAsian Pac J Cancer Prev1562956300201410.7314/APJCP.2014.15.15.629525124614 SisikAKayaMBasGBasakFAlimogluOCEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patientsAsian Pac J Cancer Prev1442894294201310.7314/APJCP.2013.14.7.428923991991 HanESLeeHHLeeJSSongKYParkCHJeonHMAt which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatmentJ Gastric Cancer14123128201410.5230/jgc.2014.14.2.12325061540 ChenXZZhangWKYangKWangLLLiuJWangLHuJKZhangBChenZXChenJPCorrelation between serum CA724 and gastric cancer: Multiple analyses based on Chinese populationMol Biol Rep3990319039201210.1007/s11033-012-1774-x22752725 EmotoSIshigamiHYamashitaHYamaguchiHKaisakiSKitayamaJClinical significance of CA125 and CA72-4 in gastric cancer with peritoneal disseminationGastric Cancer15154161201210.1007/s10120-011-0091-821892754

The positive rate of CEA, CA19-9, and CA72-4, and a parallel test of three tumor biomarkers in all patients and in subgroups. M, male; F, female; y, years; Dif, differentiated; Undif, undifferentiated; T, tumor stage; N, lymph node stage; M; M stage; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4; PARA, parallel test.

Three-dimensional scatter plot of the serum levels of CEA, CA19-9 and CA72-4. The left lower graph includes all the data, and the right upper graph includes a portion of the data (CEA, ≤10 ng/ml; CA19-9, ≤80 U/ml; and CA72-4, ≤14 U/ml). CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4.

The differences among the positive rates of CEA, CA19-9 and CA72-4 for different clinicopathological features in patients with gastric carcinoma.

Clinicopathological feature Total n CEA n (%) CA19-9 n (%) CA72-4 n (%) χ2 P-value
Gender
  Male 172 42 (24.42) 30 (17.44) 36 (20.93) 2.529 0.282
  Female 44 7 (15.91) 11 (25.00) 13 (29.55) 2.361 0.307
  χ2 1.447 1.302 1.483
  P-value 0.229 0.254 0.223
Age (years)
  ≤60 93 17 (18.28) 19 (20.43) 21 (22.58) 0.529 0.768
  >60 123 32 (26.02) 22 (17.89) 28 (22.76) 2.383 0.304
  χ2 1.807 0.223 0.001
  P-value 0.179 0.637 0.975
Histology
  Differentiated 52 10 (19.23) 8 (15.38) 9 (17.31) 0.268 0.874
  Undifferentiated 164 39 (23.78) 33 (20.12) 40 (24.39) 0.994 0.608
  χ2 0.466 0.576 1.129
  P-value 0.495 0.448 0.288
T stage
  T1–2 53 9 (16.98) 1 (1.89) 6 (11.32) 6.810 0.033
  T3–4 140 31 (22.14) 34 (24.29) 34 (24.39) 0.238 0.888
  χ2 0.623 12.992 3.933
  P-value 0.430 0.0003 0.047
  N stage
  N(−) 71 14 (19.72) 7 (9.86) 11 (15.94) 2.721 0.257
  N(+) 116 23 (18.93) 25 (21.55) 29 (25.00) 0.934 0.627
  χ2 0.0003 4.245 2.367
  P-value 0.986 0.039 0.124
M stage
  M0 193 40 (20.73) 35 (18.13) 40 (20.73) 0.543 0.762
  M1 23 9 (39.13) 6 (26.09) 9 (39.13) 1.150 0.563
  χ2 3.969 0.302 3.969
  P-value 0.046 0.583 0.046
TNM stagea
  I/II 100 21 (21.00) 12 (12.00) 14 (14.00) 3.381 0.185
  III/IV 116 28 (24.14) 29 (25.00) 35 (30.17) 1.271 0.530
  χ2 0.302 5.902 8.009
  P-value 0.583 0.015 0.005
Total cases 216 49 (22.69) 41 (18.98) 49 (22.69) 1.172 0.557

Differences in the positive rates (categorical variables) of CEA, CA72-4 and CA19-9 were analyzed using the χ2 test.

The TNM stage was determined according to the 7th edition of the International Union Against Cancer Classification (2010) (17). CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4.

Correlation between the expression of CEA, CA19-9 and CA72-4 in patients with gastric carcinoma with respect to different clinicopathological features.

CEA vs. CA19-9 CEA vs. CA72-4 CA19-9 vs. CA72-4
Clinical feature n Phi coef χ2 P-value Phi coef χ2 P-value Phi coef χ2 P-value
Gender
  Male 172 −0.012 0.023 0.879 0.173 5.166 0.023 0.140 3.378 0.066
  Female 44 0.323 0.054a 0.263 0.170a 0.316 0.057a
Age
  ≤60 years 93 0.174 0.106a 0.077 0.524a 0.300 0.011a
  >60 years 123 −0.035 0.151 0.698 0.253 7.848 0.005 0.101 1.249 0.264
Histology
  Diff 52 0.062 0.642a 0.035 1.000a 0.228 0.130a
  Undiff 164 0.041 0.278 0.598 0.216 7.678 0.006 0.175 5.043 0.025
T stage
  T1–2 53 −0.063    1.000a 0.156 0.267a 0.388 0.113a
  T3–4 140 0.059 0.488 0.485 0.139 2.715 0.099 0.145 2.960 0.085
  Tx 23 −0.071 1.000a 0.270 0.383a 0.132 0.643a
N stage
  N(−) 71 0.074 0.618a 0.179 0.209a −0.011 1.000a
  N(+) 116 0.002 1.000a 0.162 3.055 0.081 0.278 8.991 0.003
  Nx 29 0.042 1.000a 0.193 0.422 0.033 1.000a
M stage
  M0 193 0.058 0.648 0.421 0.149 4.170 0.039 0.109 7.014 0.008
  M1 23 −0.071 1.000a 0.270 0.383a 0.132 0.643a
TNM stage
  I–II 100 0.036 0.712a 0.217 0.069a 0.028 0.674a
  III–IV 116 0.047 0.251 0.616 0.156 2.819 0.093 0.228 6.015 0.014
Total cases 216 0.048 0.496 0.482 0.182 7.133 0.008 0.189 7.703 0.006

Phi correlation analysis was used to study the correlation among the expression levels of CEA, CA19-9 and CA72-4.

Fisher's exact test with two-sided P-value. Tx represents a primary tumor that cannot be assessed; Nx represents regional lymph node(s) that cannot be assessed. coef, coefficient; Diff, differentiated; Undiff, undifferentiated; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4.

Comparison of the serum levels of CEA, CA19-9 and CA72-4 with respect to different clinicopathological features in patients with gastric carcinoma.

CEA CA19-9 CA72-4
ClinPath feature n Median Z P-value Median Z P-value Median Z P-value
Gender −4.005 <0.001 0.768 0.443 0.450 0.653
  Male 172 2.465 7.450 2.510
  Female 44 1.175 12.000 2.575
Age (years) −0.440 0.660 0.459 0.647 0.001 0.999
  ≤60 93 2.310 7.500 2.820
  >60 123 2.230 7.500 2.390
Histology −0.088 0.930 −0.693 0.489 −1.483 0.138
  Diff 52 2.270 7.450 1.970
  Undiff 164 2.220 7.700 2.810
T stage −0.289 0.773 −2.376 0.018 −3.241 0.001
  T1–2 53 2.230 6.600 1.530
  T3–4 140 2.170 9.700 2.745
N stage 0.860 0.390 −1.607 0.108 −1.868 0.062
  N(−) 71 2.230 6.600 1.880
  N(+) 116 2.075 8.775 2.685
M stage 1.698 0.090 0.579 0.563 2.072 0.038
  M0 193 2.210 7.400 2.320
  M1 23 4.130 11.200 6.290
TNM stage −0.011 0.991 −2.721 0.007 −3.883 0.0001
  I/II 100 2.370 6.600 1.795
  III/IV 116 2.115 11.000 3.155

The non-parametric Wilcoxon two-sample test was used for the comparison of the differences in serum levels of the biomarkers.

Two-sided P-values. ClinPath, clinicopathological; Diff, differentiated; Undiff, undifferentiated; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4.

The correlation between serum levels of CEA, CA19-9, CA72-4 in patients with gastric carcinoma in different clinicopathological features.

CEA vs. CA19-9 CEA vs. CA72-4 CA19-9 vs. CA72-4
ClinPath feature N Coef P-value Coef P-value Coef P-value
Gender
  Male 172 0.217 0.004 0.266 0.000 0.065 0.399
  Female 44 0.376 0.012 0.330 0.029 0.465 0.002
Age
  ≤60 years 93 0.186 0.075 0.238 0.022 0.299 0.004
  >60 years 123 0.263 0.003 0.313 0.000 0.060 0.513
Histology
  Differ 52 0.285 0.041 0.342 0.013 0.018 0.901
  Undiffer 164 0.213 0.006 0.266 0.001 0.211 0.007
T-stage
  T1–2 53 0.219 0.116 0.153 0.274 −0.020 0.889
  T3–4 140 0.255 0.002 0.294 0.000 0.162 0.056
N-stage
  N(−) 71 0.207 0.083 0.112 0.354 −0.057 0.640
  N(+) 116 0.267 0.004 0.347 0.000 0.300 0.001
M-stage
  M0 193 0.251 0.000 0.255 0.000 0.174 0.015
  M1 23 0.022 0.920 0.261 0.229 0.089 0.688
TNM-stage
  I/II 100 0.211 0.036 0.297 0.002 −0.046 0.646
  III/IV 116 0.234 0.011 0.288 0.001 0.239 0.010
Total cases 216 0.231 0.001 −0.271 <.0001 0.167 0.014

Coef, Spearman's correlation coefficient; ClinPath, clinicopathological; Diff, differentiated; Undiff, undifferentiated; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4.